JP2016531889A - ヒト胎盤および造血細胞由来の細胞による治療 - Google Patents

ヒト胎盤および造血細胞由来の細胞による治療 Download PDF

Info

Publication number
JP2016531889A
JP2016531889A JP2016519848A JP2016519848A JP2016531889A JP 2016531889 A JP2016531889 A JP 2016531889A JP 2016519848 A JP2016519848 A JP 2016519848A JP 2016519848 A JP2016519848 A JP 2016519848A JP 2016531889 A JP2016531889 A JP 2016531889A
Authority
JP
Japan
Prior art keywords
cells
ucb
subject
placental perfusate
cord blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016519848A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016531889A5 (enExample
Inventor
ピー．グルネイ ジョディ
ピー．グルネイ ジョディ
ズハング キアオクイ
ズハング キアオクイ
ハーブ ステイシー
ハーブ ステイシー
ジェイ．ハリリ ロバート
ジェイ．ハリリ ロバート
Original Assignee
アントフロゲネシス コーポレーション
アントフロゲネシス コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アントフロゲネシス コーポレーション, アントフロゲネシス コーポレーション filed Critical アントフロゲネシス コーポレーション
Publication of JP2016531889A publication Critical patent/JP2016531889A/ja
Publication of JP2016531889A5 publication Critical patent/JP2016531889A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2016519848A 2013-10-03 2014-10-02 ヒト胎盤および造血細胞由来の細胞による治療 Pending JP2016531889A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361886648P 2013-10-03 2013-10-03
US61/886,648 2013-10-03
US201361890057P 2013-10-11 2013-10-11
US61/890,057 2013-10-11
PCT/US2014/058774 WO2015051088A1 (en) 2013-10-03 2014-10-02 Therapy with cells from human placenta and hematopoietic cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019112450A Division JP2019194211A (ja) 2013-10-03 2019-06-18 ヒト胎盤および造血細胞由来の細胞による治療

Publications (2)

Publication Number Publication Date
JP2016531889A true JP2016531889A (ja) 2016-10-13
JP2016531889A5 JP2016531889A5 (enExample) 2018-04-19

Family

ID=52779130

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016519848A Pending JP2016531889A (ja) 2013-10-03 2014-10-02 ヒト胎盤および造血細胞由来の細胞による治療
JP2019112450A Withdrawn JP2019194211A (ja) 2013-10-03 2019-06-18 ヒト胎盤および造血細胞由来の細胞による治療
JP2021065060A Withdrawn JP2021107407A (ja) 2013-10-03 2021-04-07 ヒト胎盤および造血細胞由来の細胞による治療
JP2023027978A Pending JP2023078156A (ja) 2013-10-03 2023-02-27 ヒト胎盤および造血細胞由来の細胞による治療

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019112450A Withdrawn JP2019194211A (ja) 2013-10-03 2019-06-18 ヒト胎盤および造血細胞由来の細胞による治療
JP2021065060A Withdrawn JP2021107407A (ja) 2013-10-03 2021-04-07 ヒト胎盤および造血細胞由来の細胞による治療
JP2023027978A Pending JP2023078156A (ja) 2013-10-03 2023-02-27 ヒト胎盤および造血細胞由来の細胞による治療

Country Status (12)

Country Link
US (1) US10179152B2 (enExample)
EP (1) EP3052109B8 (enExample)
JP (4) JP2016531889A (enExample)
KR (3) KR20160102965A (enExample)
CN (1) CN105792834A (enExample)
AU (3) AU2014329513A1 (enExample)
CA (1) CA2926199C (enExample)
DK (1) DK3052109T3 (enExample)
MX (2) MX2016004209A (enExample)
RU (2) RU2019131152A (enExample)
WO (1) WO2015051088A1 (enExample)
ZA (1) ZA201602151B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10456423B2 (en) 2016-06-13 2019-10-29 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same
US10426796B2 (en) 2016-06-13 2019-10-01 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same
US11285177B2 (en) 2018-01-03 2022-03-29 Globus Medical, Inc. Allografts containing viable cells and methods thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004528021A (ja) * 2001-02-14 2004-09-16 アンスロジェネシス コーポレーション 分娩後の哺乳動物の胎盤、その使用およびそれに由来する胎盤幹細胞
WO2007089627A2 (en) * 2006-01-27 2007-08-09 Auxocell Laboratories, Inc. Methods and compositions relating to stem cell transplantation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5437994A (en) * 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
IL107483A0 (en) * 1993-11-03 1994-02-27 Yeda Res & Dev Bone marrow transplantation
AU2004212009B2 (en) * 2003-02-13 2010-07-29 Celularity Inc. Use of umbilical cord blood to treat individuals having a disease, disorder or condition
AU2006332679A1 (en) * 2005-12-29 2007-07-12 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
CN105087490A (zh) * 2006-05-11 2015-11-25 脐血科技公司 收集和使用胎盘脐血干细胞的方法
CA2700617C (en) * 2007-09-28 2018-11-06 Celgene Cellular Therapeutics Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004528021A (ja) * 2001-02-14 2004-09-16 アンスロジェネシス コーポレーション 分娩後の哺乳動物の胎盤、その使用およびそれに由来する胎盤幹細胞
WO2007089627A2 (en) * 2006-01-27 2007-08-09 Auxocell Laboratories, Inc. Methods and compositions relating to stem cell transplantation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BEST PRACT. RES. CLIN. HAEMATOL., vol. 23, JPN6018020154, 2010, pages 291 - 303, ISSN: 0003977211 *
CELL RES., vol. 15, no. 7, JPN6018020157, 2005, pages 539 - 547, ISSN: 0003977212 *

Also Published As

Publication number Publication date
US10179152B2 (en) 2019-01-15
CA2926199C (en) 2022-05-17
EP3052109A4 (en) 2017-05-03
KR20220044384A (ko) 2022-04-07
WO2015051088A1 (en) 2015-04-09
ZA201602151B (en) 2022-12-21
KR20160102965A (ko) 2016-08-31
JP2023078156A (ja) 2023-06-06
KR20210054046A (ko) 2021-05-12
MX2016004209A (es) 2016-07-11
EP3052109B1 (en) 2021-05-12
DK3052109T3 (da) 2021-08-16
AU2014329513A1 (en) 2016-04-28
US20160235790A1 (en) 2016-08-18
RU2019131152A3 (enExample) 2022-02-24
EP3052109A1 (en) 2016-08-10
MX2021003798A (es) 2021-05-27
EP3052109B8 (en) 2021-06-23
JP2019194211A (ja) 2019-11-07
NZ718571A (en) 2023-12-22
CN105792834A (zh) 2016-07-20
RU2016116816A (ru) 2017-11-13
RU2019131152A (ru) 2019-11-11
RU2016116816A3 (enExample) 2018-08-02
CA2926199A1 (en) 2015-04-09
AU2022215207A1 (en) 2022-09-01
JP2021107407A (ja) 2021-07-29
AU2020202076A1 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
JP2023078156A (ja) ヒト胎盤および造血細胞由来の細胞による治療
DK2217329T3 (en) APPLICATION OF NAVLINE BLOOD IN THE TREATMENT OF COMPLIANCES IN CONNECTION WITH PREGNANCY BIRTH
Elchalal et al. Postpartum umbilical cord blood collection for transplantation: a comparison of three methods
Broxmeyer et al. Cord blood hematopoietic cell transplantation
WO2019084546A1 (en) INCREASE IN FERTILITY BY PLASMA RICH IN PLATELETS
KR20080027295A (ko) 혈장-제거되고, 적혈구-비제거된 제대혈 조성물 및 사용방법
Sivakumaran et al. Umbilical cord blood banking and its therapeutic uses
HK1227309A1 (en) Therapy with cells from human placenta and hematopoietic cells
HK1227309B (en) Therapy with cells from human placenta and hematopoietic cells
US20170042944A1 (en) Treatment of conditions and complications in infants
CN104721232A (zh) 脐带血免疫细胞在制备治疗银屑病药物中的应用
CN114466655A (zh) 心血管疾病的治疗
Eze et al. Umbilical Cord Blood Collection Protocol and the Impact on the Nucleated and Progenitor Cell Quantity and Quality
Pfalzgraf et al. Autotransfusion in obstetrics: a narrative review
Dasari et al. Prevention of transfusion reactions and in post transfusion reactions, promoting patient safety [3P’s]
Sharma et al. A study of 120 umbilical cord whole blood transfusions in 77 patients with different clinical conditions
Losee Blood transfusion in obstetrics
Solves et al. Unrelated Cord Blood Banking and Transplantation: Implications for Obstetricians
Afreen et al. Evaluation of procedures for quantification of CD34 haematopoietic stem cells and viability studies in umbilical cord blood derived mononuclear cells.
Andritsos et al. Collection, processing, and infusion of adult hematopoietic stem cells (bone marrow and peripheral blood stem cells)
Talaulicar Systemic aortoarteritis: a case review
Yasmin et al. Umbilical Cord Blood Saving-A Lifeline for a Lifetime
Andritsos et al. 27 Collection, Processing, and Infusion of Adult Hematopoietic Stem Cells (Bone
Tan et al. Collection, Processing, and Infusion of Adult Hematopoietic Stem Cells (Bone Marrow and Peripheral Blood Stem Cells)
HK1124484B (en) Plasma-depleted, non-red blood cell-depleted cord blood compositions and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170929

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180605

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180830

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190219